Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer

Publisher: Blackwell Publishing

E-ISSN: 1097-0142|121|23|4165-4172

ISSN: 0008-543X

Source: Cancer, Vol.121, Iss.23, 2015-12, pp. : 4165-4172

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Treatment options for patients with non–small cell lung cancer (NSCLC) with brain metastases are limited. Patupilone (EPO906), a blood-brain barrier–penetrating, microtubule-targeting, cytotoxic agent, has shown clinical activity in phase 1/2 studies in patients with NSCLC. This study evaluates the efficacy, pharmacokinetics, and safety of patupilone in NSCLC brain metastases. This is the first prospective study of chemotherapy for recurrent brain metastases from non–small cell lung cancer. In this population, patupilone demonstrates activity in heavily treated patients.

Related content